A patient-education program model with 18 criteria was refined into a survey instrument and sent to 217 Michigan hospitals. Of these, 181 hospitals and one free-standing clinic responded, with 47 indicating they had no applicable programs and 135 providing data on 281 existing patient-education programs. A mean (+/- SD) of 12.1 +/- 3.9 criteria were met. The range included two programs that met only one criterion and 15 that met all 18. After it was established that the criteria operated independently of each other, six factors were analyzed to observe their impact on the number of criteria met by the 281 programs. Analysis of variation (ANOVA) showed that presence and type of program coordinator accounted for 17% of explained variance, subject for 8%, hospital size for 4.4%, existence of a defined budget for 4%, and geographic location for 3%. Because of unequal numbers, the full-time/part-time coordinator factor was not included in the ANOVA. More than one third of the variance affecting numbers of criteria met by patient-education programs was explained by these factors.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0738-3991(83)90005-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Efficacy of Repetitive Transorbital Alternating Current Stimulation (rtACS) in Patients With Optic Nerve Damage: A Systematic Review and Meta-Analysis.
Cureus
December 2024
Department of Ophthalmology, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Jeddah, SAU.
Optic nerve disorders significantly contribute to visual impairment with irreversible visual deficits. Current treatments have limited efficacy in resolving chronic visual deficits, necessitating novel therapeutic strategies. Neurorehabilitation techniques, including repetitive transorbital alternating current stimulation (rtACS), have emerged as promising approaches to restore lost visual function through the ability to modulate brain activity.
View Article and Find Full Text PDFCase report: Relapse of intrathyroidal parathyroid carcinoma in a patient with novel variants in and genes.
Front Oncol
January 2025
Administration, Endocrinology Research Center, Moscow, Russia.
Parathyroid carcinoma (PC) is one of the rarest malignant neoplasms of the human endocrine system, with a prevalence of approximately 0.005% of all oncological diseases. Despite its indolent course, PC generally relapses in about 40%-60% of cases.
View Article and Find Full Text PDFAnalysis of physical activity levels and influencing factors in cancer survivors after pancreaticoduodenectomy.
Front Oncol
January 2025
Nursing Department, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Introduction: Physical activity is becoming more important in cancer patient care. However, there are limited studies investigating physical activity levels in cancer survivors after pancreaticoduodenectomy. This study aims to assess the present status of physical activity levels in cancer survivors after pancreaticoduodenectomy and whether perioperative metrics and length of follow-up have an impact on physical activity levels in survivorship.
View Article and Find Full Text PDFPrognostic and clinicopathological significance of mucin family members expression in gastric cancer: a meta-analysis.
Front Oncol
January 2025
Department of Pancreatic and Gastric Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Background: Mucin family members have been reported to be widely expressed in gastric carcinoma with diverse functions. Several important mucins exert the function of tumorigenesis or progression in gastric cancer (GC). Here, we conduct this meta-analysis to evaluate the association between mucin expression and clinicopathological features in GC.
View Article and Find Full Text PDFNISCAHN: a phase II trial of nivolumab in patients with salivary gland carcinoma (Unicancer ORL-08).
BMJ Oncol
October 2023
Biostatistics Department, Centre Leon Berard, Lyon, France.
Objective: Salivary gland cancers (SGC) are rare cancers with currently no standard treatment for recurrent/metastatic disease. Based on checkpoint inhibitors benefit in a broad range of tumours, NIvolumab in Salivary gland CArcinoma of the Head and Neck (NISCAHN) evaluated nivolumab efficacy in SGC.
Methods And Analysis: In this phase II single-stage Fleming design, patients with SGC with a progressive disease progression within 6 months prior to entering the study, were divided into ACC (adenoid cytic carcinoma) and non-ACC.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!